The 16th European Headache Congress was held in Vienna, Austria, and online, on 7-10 December 2022, with the theme of ‘Moving to a Headache-less Future’.
Salivary CGRP may predict response to anti-CGRP therapies, and patients with episodic migraine, less frequent migraine and a good response to triptans are more likely to be super-responders to CGRP mAbs.1.2 These were the conclusions from two studies investigating opportunities for precision medicine for migraine that were presented at the conference. In a further reported …
Read more »Latest evidence about mandatory, annual CGRP mAb holidays suggests that migraine rapidly deteriorates in most patients and may add to anxiety.1,2 In a study of 154 patients who took erenumab, fremanezumab or galcanezumab for 12 month, 85% felt they had deteriorated during a mandatory two or three month drug holiday and, in seven per cent, …
Read more »Further evidence that some patients benefit from switching CGRP mAbs – particularly from agents active at the CGRP receptor to those affecting circulating CGRP – comes from studies in the UK and Portugal.1,2 In a prospective audit carried out at a London headache centre in the UK, 33 patients with chronic migraine received a median …
Read more »Approximately half of patients with chronic cluster headache (CCH) may benefit from galcanezumab, according to data from two small real world studies from university researchers in Seville and Valencia, Spain.1,2 In a prospective observational study of 21 patients with CCH who received at least one dose of galcanezumab 240 mg, mean monthly headache attacks were …
Read more »Brain connectivity modifications in the default mode network (DMN) have been recorded in patients with episodic and chronic migraine after three months of CGRP mAb treatment. At baseline and after three months of CGRP mAb treatment, 26 patients with migraine underwent a 128 channel HD-EEG recording with the aim of investigating connectivity changes in the …
Read more »Erenumab is more cost effective than topiramate as first line treatment of episodic migraine (EM) and its incremental cost utility ratio (ICER) is lower than the accepted cost effectiveness threshold in Spain. This was the conclusion from cost effectiveness modeling based on clinical outcomes and discontinuation rates from pivotal erenumab clinical trials including the HER-MES …
Read more »Two thirds of people start CGRP mAbs for efficacy reasons and approximately one in seven switch medications, according to data from the OVERCOME (EU) observational survey of migraine care in 2167 patients in Germany and Spain.1 Of those in OVERCOME who switched, 62% listed access or economic reasons, and 44% listed a recommendation or request …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
